David Reynolds is our Chief Scientific Advisor, having previously held the post of Chief Scientific Officer at Alzheimer’s Research UK for three years.
Read full biography
David now works for the Dementia Discovery Fund, the world’s largest venture fund focused on discovering and developing novel therapies for dementia, including Alzheimer’s disease. His role is focussed on creating biotech companies that translate UK dementia science into drug discovery activities, including research that has been supported by ARUK.
Previously David has worked in the pharmaceutical industry for 18 years at Merck Sharp & Dohme, Lundbeck and latterly Pfizer, where he was the Cambridge Neuroscience & Pain research site head. He has held a variety of R&D leadership roles with responsibilities ranging from exploratory biology, through drug discovery, early clinical development and business development in multiple disease areas, but with a focus on neuroscience and pain.
He has served as a member of the Medical Research Council’s Neuroscience and Mental Health Board, various ad hoc advisory boards and also provides expert drug discovery advice to neuroscience biotechs. David holds a BA in Natural Sciences and a PhD in Neuropharmacology both from the University of Cambridge and is a visiting professor at the Institute of Neurology at University College London.